The FDA Price-Tag Paradox: Why Your Accelerated Drug Approval Now Depends On Your Monthly Premium
WASHINGTON — In a stunning development that defies both medical science and basic economics, the Food and Drug Administration yesterday announced it would consider a patient’s ability to pay before approving certain cancer treatments. The new policy, titled ‘Patient Financial Readiness Assessment Framework,’ reportedly will evaluate not just a drug’s safety and efficacy, but also whether the patient has sufficient income to afford it before it can be prescribed.
‘This is a transformative step in healthcare equity,’ FDA Commissioner Robert Califf told a packed room at the agency’s headquarters. ‘No longer will we approve treatments that patients simply cannot access. Now, if you can’t afford your medicine, we won’t approve it for you. It’s not that we’re denying access — it’s that we’re requiring upfront financial clearance.’